"I am excited to help develop the clinical evidence that will support the DELFI platform's use in multiple applications. "Widely accessible screening for our deadliest cancers has the potential to have a major impact on cancer mortality and public health," Dr. He received a PhD in Microbiology and Immunology from Indiana University. Before that, he managed multiple clinical studies at Merck. Prior to Roche, Dave led Clinical Affairs at Endocyte, a clinical-stage pharmaceutical company acquired by Novartis in 2018, focusing on both therapeutic and companion diagnostic clinical evidence generation. "With multiple clinical studies already underway, Dave's leadership will be invaluable as we advance DELFI's rich pipeline of products designed to save lives by detecting cancer at its earliest stages." "I am very excited to add Dave's experience developing oncology diagnostics and therapeutics to DELFI's leadership team," said Victor Velculescu, MD, PhD, DELFI's Founder and CEO. Roche is one of the largest global pharmaceutical companies and is based. Dave joins DELFI from Roche Diagnostics, where he spent more than a decade in clinical development roles focused on oncology screening and diagnostic products, most recently as Global Head of Clinical Development for Oncology and Genetics. This statistic shows pharmaceutical company Roche's top diagnostic products in 2020, based on revenue. BALTIMORE and PALO ALTO, Calif., J/PRNewswire/ - DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Dave Morgenstern, PhD, as Vice President of Clinical Development.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |